I'm not sure I agree that Aldoxorubicin targets the tumor better than Doxil, but you may be right. However the half life of Doxil is on the order of days ( like 2 and a half days ).
It's true that STS trials rarely show an improvement in OS results, but the upcoming results I think have a reasonable chance to improve OS and that is very exciting.
That's a great way to get started money1469. You have to understand that the stock touting scandal, no matter how vapid, will follow this company like a ball n chain into the future and that's why it remains in earth orbit.
Can't believe with all the positive information flow this stock continues to get hit, already have 200 shares and will be adding to position prior to year in, hopefully can build base of 1000 shares below the 2.70 range. Risks vs Reward is to great to ignore.
Sentiment: Strong Buy
meltdownman ~ the thumbs down you received was an accident on my part, the result of big fingers/small cellphone. So sorry. I think we have to trust a bit in the trial leaders to have structured the GBM phase 2 to account for these things. Tumor shrinkage, at any stage in GBM, is difficult to assess short of a postmortem analysis. That said, I think we'll be ok.
As for where Aldoxorubicin will be applied, to what disease spaces, that's relatively easy to answer. Anywhere dox is already used. I'm an expert at nothing and know little of the science involved in the gamut of Dox use. What I can tell you, is that management is narrowing the focus to those indications that are most promising.
Hope that helps. And go CytRx!
My only concern on the treatment of patients with brain cancer is the makeup of the population of cancer patients. If I recall correctly these are patients who have nothing left to lose meaning that it may even be too late for Aldo. I would think that this would distort the data don't you think which in turn would be a negative? In addition, if a patient is that far along with brain cancer, the bodies uptake may be limited than say someone with much earlier stages of brain cancer don't you think? I am not a biologist but just questioning whether or not the docs at CYTR need to be promoting Aldo more to patients with earlier stages of brain cancer than the current population. However, the fact that this technology is being applied to a lot more forms of cancer is encouraging. I would be interested to see if it could ever be used for prostate and breast cancer. I don't know if Dox is even applicable to those forms of cancer but the link technology might be able to be applied to the meds used to treat those forms of cancer. Any ideas why it is not be used for breast and prostate cancers?
Sentiment: Strong Buy
Lawsuit is a joke ..if you are selling on that its a mistake / ITS almost load the boat time
for end of 2014/beginning of 2015 data
bfishe ~ I did not know about this trial failure and I thank you for brining it to my attention. For the past 8 months, I went all left brained analytical instead of right brained thaumaturgical and lost big-time. I'm now back to doing what I do best.
Aldoxorubicin will likely fair better than Doxil for the simple fact that it targets the tumor better to a factor of infinity and has a half-life of about 24 hours as opposed to 5 minutes for dox. I'm curious, are control arms the norm in pre-clinical animal trials. If yes, then the probably avoided that for obvious reasons.
Remember, this is an aggressive and tactical company.
Lastly, OS isn't normally enhanced in STS which is why PFS is the primary endpoint. That said, this is a tactical enterprise ;-)
That can't be true. Short position in SSH - Bing! Short position in MNKD pre-adcom - Bing! Long NVAX Bing, Bing, Bing, Bing. Long AMRN prior to Jenkin's appeal decision - Bing! Long NKTR leading up to Movantik approval - Bing!
The fact is, you have to read a blogger's opinion with discernment. And I NEVER recommend holding through a binary event. And, I've never referred to myself as an expert. I'm a rank a mature with a love of biotech which overall has performed poorly this year. That said, my portfolio of trades posted on my website is up 40.8% this year and 60.7% this past two years.
View my upcoming videos on trading in the sector and you (and your friend) will do better.
I agree with your "perception" argument which is why I indicate in my video that the stock will remain subject to short interest and therefore behave much like a yo-yo. I disagree on determining the merit, or lack thereof, of these lawsuits. It's simple really. Did the phase 2 results cause the buoyant rise in the stock price or the opinion pieces in financial blogs. I believe the former.
and the FDA is fully vested in seeing a more efficacious drug on the market than doxil.
the momo's and the yoyo's hammered the stock down amidst cries of fraud, etc etc against the CEO. When the stock hit $22 I SMILED AND TOOK THE BEAN, it went on to hit $27, CYTR will do the same. I've never heard of a drug with multiple Orphan Drug statitses in USA and Europe. Hold on for the ride, check out FONR's chart if you want a lesson in accelerated appreciation. Aldoxorubicin is now becoming a money maker that will replace doxorubicin to the tune of billions.